Page last updated on December 27, 2024
CITIUS ONCOLOGY, INC. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-12-27 17:00:41 EST.
Filings
10-K filed on 2024-12-27
CITIUS ONCOLOGY, INC. filed a 10-K at 2024-12-27 17:00:41 EST
Accession Number: 0001213900-24-113150
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
Item 1C. Cybersecurity Risk Management and Strategy The Company has established processes to assess, identify , and manage risks from cybersecurity threats as part of our broader enterprise-wide risk management system and processes, which is overseen by our Board of Directors through our Audit Committee, along with our executive management. Our cybersecurity program focuses on all areas of our business, including cloud-based environments, devices used by employees and contractors, facilities, networks, applications, vendors, disaster recovery, business continuity and controls and safeguards enabled through business processes and tools. We continuously monitor for unauthorized access to our information technology systems and identify potential security threats through various automated detection solutions. To protect the security of our information infrastructure and protect our systems and information from unauthorized access, we draw on the knowledge and insights of an external information technology consultant who acts as our primary IT administrator and employ an array of third-party tools and technologies. As of the date of this Annual Report, we have not encountered any risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company, including its business strategy, results of operations, or financial condition. For more information on our cybersecurity related risks, see “Risk Factors - Risks Related to Our Business and Our Industry” included elsewhere in this Annual Report on Form 10-K. Governance The Board of Directors is responsible for overseeing our enterprise risk management program. The Audit Committee of the Board of Directors has been designated by the Board to oversee cybersecurity risks and our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee receives updates on cybersecurity and information technology matters and related risk exposures from our Chief Financial Officer (“CFO”). The CFO oversees the operation of our cybersecurity program and has 10 years of executive experience overseeing risk management and internal controls. The CFO is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents through the CFO’s oversight of the Company’s information technology function and supervision of the Company’s IT administrator.
Company Information
Name | CITIUS ONCOLOGY, INC. |
CIK | 0001851484 |
SIC Description | Pharmaceutical Preparations |
Ticker | CTOR - Nasdaq |
Website | |
Category | Emerging growth company |
Fiscal Year End | September 29 |